Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
Antonio J Vallejo-VazSarah BrayGuillermo VillaJulia BrandtsGaia KiruJennifer MurphyMaciej BanachStefano De ServiDan GaitaIoanna Gouni-BertholdG Kees HovinghJacek J JozwiakJ Wouter JukemaRobert Gabor KissSerge KownatorHelle K IversenVincent MaherLuis MasanaAlexander ParkhomenkoAndré PeetersPiers CliffordKatarina RaslovaPeter SiostrzonekStefano RomeoDimitrios TousoulisCharalambos VlachopoulosMichal VrablikAlberico L CatapanoNeil R PoulterKausik K Raynull nullPublished in: Cardiovascular drugs and therapy (2022)
In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.